Elga Lohler - Smith Nephew Chief Human Resource Officer
SNNUF Stock | USD 14.60 0.60 4.29% |
Executive
Ms. Elga Lohler is Chief Human Resource Officer of the Company. She joined Smith Nephew in January 2002 as Director of HR and has since held progressively senior positions in Wound Management, Operations, Corporationrationrate Functions and Group. Elga became Chief Human Resources Officer in December 2015 and leads the Global Human Resources, Internal Communication and Sustainability Functions. Elga is based in Fort Worth, US. Skills and Experience Elga has more than 25 years Human Resources experience. Prior to joining Smith Nephew, Elga held Human Resources roles at Transnet, Sensormatic and Advanced Tissue Sciences, which was acquired by Smith Nephew in 2002. Through these roles, Elga has developed deep expertise in strategy planning and development, organisational design and effectiveness, restructuring and integration and transformational change in support of business objectives. In her current roles, Elga is responsible for driving Smith Nephews human capital strategy across the enterprise in support of the company overall business plan and strategic direction. Elga holds an undergraduate degree in Psychology and a Masters degree in Organizational Psychology, both from the University of Witwatersrand in South Africa. since 2015.
Age | 55 |
Tenure | 10 years |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Michael Donovan | Axogen Inc | 59 | |
Natalia Kozmina | LivaNova PLC | N/A | |
Michael Parks | Lucid Diagnostics | N/A | |
Craig Swandal | Axogen Inc | 64 | |
Matthew III | LivaNova PLC | N/A | |
Yuliya Aslan | Paragon 28 | N/A | |
Kimberly Lockwood | CONMED | N/A | |
Todd Puckett | Axogen Inc | N/A | |
Jeff Sears | Paragon 28 | N/A | |
Hans Kestler | Paragon 28 | N/A | |
Lisa Wolf | Tivic Health Systems | 62 | |
Victoria MD | Lucid Diagnostics | N/A | |
Harold MBA | Axogen Inc | N/A | |
Stephen Deitsch | Paragon 28 | 52 | |
Robert JD | Paragon 28 | 58 | |
Trui Hebbelinck | LivaNova PLC | 52 | |
Kenneth Washington | Medtronic PLC | 65 | |
Deanna Wilke | LivaNova PLC | N/A | |
Daniel Esq | CONMED | 60 | |
Jonathan Friedman | Paragon 28 | 53 | |
Mark Karshner | Orthopediatrics Corp | N/A |
Management Performance
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alison Parkes, Chief Officer | ||
Paul Connolly, Pres Operations | ||
Deepak Nath, CEO Director | ||
Joe Metzger, VP Communications | ||
Andrew Swift, VP Relations | ||
AnneFrancoise Nesmes, CFO Director | ||
Helen Barraclough, Company Counsel | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, Sports Orthopaedics | ||
Philip Cowdy, Chief Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 | |||
Profit Margin | 0.1 % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 14.08 B | |||
Shares Outstanding | 873.35 M | |||
Shares Owned By Insiders | 0.17 % | |||
Shares Owned By Institutions | 52.60 % | |||
Price To Earning | 23.41 X | |||
Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Smith Pink Sheet
Smith Nephew financial ratios help investors to determine whether Smith Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Smith with respect to the benefits of owning Smith Nephew security.